Bioptik Technology Incorporation (4161) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bioptik Technology Incorporation (4161:TWSE), powered by AI.

Current Price
$22.95
Sector
Healthcare
What is the Bioptik Technology Incorporation stock price forecast?

Bioptik Technology Incorporation is currently trading at $22.95. View real-time AI analysis on Alpha Lenz.

What is Bioptik Technology Incorporation insider trading activity?

View the latest insider trading data for Bioptik Technology Incorporation on Alpha Lenz.

What is Bioptik Technology Incorporation's P/E ratio?

View Bioptik Technology Incorporation's valuation metrics on Alpha Lenz.

Bioptik Technology Incorporation

TWSE · 4161
NT$22.95+0.05(+0.22%)
Ask about Bioptik Technology Incorporation's future dividend policy...
Alpha Chat Insight

Bioptik Technology Incorporation's ROE is 7.6%. Explore profitability and growth together.

Ask for details

Company Overview

Bioptik Technology Incorporation is a healthcare technology company specializing in the development, manufacture, and distribution of medical devices and diagnostics, as well as beauty and health products. Founded in 1999 and headquartered in Taiwan, the company is notable for its advanced blood glucose, cholesterol, and uric acid monitoring systems—which it markets under the EasyMate and Easy Touch brands—aimed at both clinical and home-use segments. Bioptik Technology also produces testing strips for these systems and offers a robust line of hyaluronic acid-based skincare and cosmetic products, distributed under the ACUREAL label. In addition to its healthcare focus, the company is involved in health supplements and has research efforts in bioenergy and biotechnology, reflecting a commitment to continuous innovation. Bioptik’s products are distributed across domestic and international markets, serving healthcare providers, laboratories, and consumers. The company positions itself as a pillar of innovation in the Taiwanese medical technology sector, emphasizing in-house R&D, quality assurance, and customer satisfaction in its pursuit of improving health monitoring and personal wellness.

SectorHealthcare
IndustryMedical Devices
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$837.19MRevenue
0.00Shares Out
0Employees

Margins

29.09%Gross
14.99%EBITDA
7.95%Operating
10.19%Pre-Tax
8.34%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

2.93%Rev 3Yr
11.51%Rev 5Yr
19.22%Op Inc 3Yr
N/AOp Inc 5Yr
14.09%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

4.57%ROA
7.61%ROE
6.07%ROIC

Financial Health

NT$399.30MCash & Cash Equivalents
NT$197.84MNet Debt
61.27%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Bioptik Technology Incorporation (ticker: 4161) is a company listed on TWSE in the Healthcare sector (Medical Devices).

The current price is 22.95 with a P/E ratio of -x and P/B of -x.

ROE is 7.61% and operating margin is 7.95%. Annual revenue is $837M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Bioptik Technology Incorporation (4161) Stock Forecast 2026 $22.95 — Price, Financials & Analyst Targets | Alpha Lenz